Abstract
The development of multidrug resistance (MDR) to chemotherapy is a major obstacle for the successful treatment of cancer. A number of mechanisms have been postulated to account for MDR in cancer. The most common and best-studied mechanism of resistance is mediated through the drug efflux protein P-glycoprotein (P-gp), which is overexpressed in drug-resistant cancer cells and is responsible for the removal of many chemotherapeutic agents. Therapeutic nanoparticles (NPs) have emerged as an innovative and promising option to combat P-gp-mediated MDR and have shown enhanced therapeutic efficacy and reduced toxicity compared to their small molecule counterparts. This review focuses on recent studies using therapeutic NPs to circumvent P-gp-mediated MDR in cancer therapy. The advantages and strategies by which therapeutic NPs were used to overcome P-gp-mediated MDR in cancer are discussed.
Keywords: P-glycoprotein, multidrug resistance, nanotechnology, drug delivery, therapeutic nanoparticles, cancer chemotherapy.
Current Pharmaceutical Design
Title:Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Volume: 19 Issue: 37
Author(s): Qiu Zhang and Fei Li
Affiliation:
Keywords: P-glycoprotein, multidrug resistance, nanotechnology, drug delivery, therapeutic nanoparticles, cancer chemotherapy.
Abstract: The development of multidrug resistance (MDR) to chemotherapy is a major obstacle for the successful treatment of cancer. A number of mechanisms have been postulated to account for MDR in cancer. The most common and best-studied mechanism of resistance is mediated through the drug efflux protein P-glycoprotein (P-gp), which is overexpressed in drug-resistant cancer cells and is responsible for the removal of many chemotherapeutic agents. Therapeutic nanoparticles (NPs) have emerged as an innovative and promising option to combat P-gp-mediated MDR and have shown enhanced therapeutic efficacy and reduced toxicity compared to their small molecule counterparts. This review focuses on recent studies using therapeutic NPs to circumvent P-gp-mediated MDR in cancer therapy. The advantages and strategies by which therapeutic NPs were used to overcome P-gp-mediated MDR in cancer are discussed.
Export Options
About this article
Cite this article as:
Zhang Qiu and Li Fei, Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles, Current Pharmaceutical Design 2013; 19 (37) . https://dx.doi.org/10.2174/1381612811319370009
DOI https://dx.doi.org/10.2174/1381612811319370009 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Challenges in Breast Cancer Control in Malaysia
Current Women`s Health Reviews Anti-Inflammatory and Anti-Neoplastic Actions of Resveratrol
Current Nutrition & Food Science Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension
Current Cancer Drug Targets Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy
Current Topics in Medicinal Chemistry Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer
Current Cancer Drug Targets Endoglin (CD105): A Target for Anti-angiogenetic Cancer Therapy
Current Drug Targets The Clinical Perspective on Value of 3D, Thin Slice T2-Weighted Images in 3T Pelvic MRI for Tumors
Current Medical Imaging Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Imaging Virus-Associated Cancer
Current Pharmaceutical Design SV40 and HIV Sequences in the Cerebrospinal Fluid of a Patient with AIDS Dementia Complex
Current HIV Research Teratogenic Activity of HDAC Inhibitors
Current Pharmaceutical Design Synergy in Plant Medicines
Current Medicinal Chemistry Plumbagin Inhibits Breast Tumor Bone Metastasis and Osteolysis by Modulating the Tumor-Bone Microenvironment
Current Molecular Medicine Multifuntional Nanoparticles: Preparation and Applications in Biomedicine and in Non-Invasive Bioimaging
Recent Patents on Nanotechnology The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Combinatorial Application of Nucleic Acid-Based Agents Targeting Protein Kinases for Cancer Treatment
Current Pharmaceutical Design